TX-MAVENIR
11.7.2022 15:02:06 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced multiple Communications Service Providers (CSPs) are upgrading their Business Support System (BSS) with Mavenir’s Digital Enablement Platform (MDE) to offer new digital services that monetize 5G network investments.
MDE is a cloud-native, catalog-driven digital BSS that enables CSPs to easily create new 5G digital offerings or complete the 5G network transformation with charging and mediation functions and can also be used to design a digital marketplace experience, bundling cross-industry partner products and services into unified offerings. “With Mavenir’s MDE platform, CSPs can innovate fearlessly by rapidly introducing new services, and capture their customers’ interest, to become an integral part of their digital life,” said Sandeep Singh, GM Digital Enablement at Mavenir.
MDE can run as a comprehensive BSS or importantly, as a digital overlay with existing legacy BSS for minimal risk and disruption. BSS digital overlay systems can help CSPs to maximize returns in the 5G era. Analysys Mason forecasts, “The digital overlay approach can also reduce costs considerably, potentially saving CSPs up to 50% over 3-5 years when compared with traditional transformation approaches.1 ”
Recent deployment examples of Mavenir’s MDE include:
- A leading CSP in Japan for business-to-business (B2B) mobility services
CSP successfully launched its Mobility Bundle Services targeted toward business customers. The typical service includes a bundle of SIM+Handsets purchased in bulk (10s-1000s). The BSS provided a first-of-its-kind agile, co-development, automated CI/CD enabling quarterly updates including modules like Product Catalog, CRM, CPQ, Order Management, Provisioning, Inventory tracking, Offline Rating & Charging, Billing, Invoicing, Payments and Collections.
Mavenir’s digital BSS, deployed as overlay BSS, is the primary for managing B2B customer account lifecycle and connects back to the existing consumer BSS, to leverage capabilities for Individual SIM activation, Number Portability workflow, Resource Inventory management and Network Mediation.
Deployment is on CSP's private cloud over the Kubernetes-based Containers-as-a-Service (CaaS) and Platform as a service (PaaS) layer.
- Large MVNO in Germany transitioning to MNO deploying MDE converged charging system (CCS) & Charging Gateway Function (CGF) for 4G+5G Converged Charging
Transitioning to becoming an MNO with owned RAN, Core, IT, BSS, and Charging system. The CCS includes the 4G OCS enabling Voice, SMS, Data service rating, and charging on real-time Diameter interfaces by integrating with the EPC and IMS network elements. The same core CCS engine also includes 5G CHF, integrated with Mavenir 5GC (5G Core) NFs. The Charging Gateway Function (CGF), also part of the CCS solution, provides for a modern microservice-based network and billing mediation functionality. While the first set of services, including 5G FWA is expected to go live in 2022, the solution is designed to deliver charging for Voice, Messaging, Data (4G+5G eMBB) and IoT in truly agile CI/CD based updates over the next two years. Deployment is on CSP's private cloud over the Kubernetes-based CaaS and PaaS layer.
- Greenfield CSP in Guyana selects MDE for E2E BSS and Charging
Deploying end-to-end BSS and Charging for their 4G+5G Mobile and Fixed Wireless service rollout. The first phase of this multi-phase enables the CSP to launch Prepaid LTE Voice, Data, and SMS services in 2022, leveraging a 4G OCS (Online Charging System) solution for prepaid voice, data, and messaging charging. The second phase will introduce Postpaid services built on top of the BSS. The final phase includes the launch of the 5G eMBB service that will be deployed using MDE 5G CCS integrated with the other vendor's 5GC.
Supporting material:
Mavenir Digital Enablement (MDE) Solution Brief
MDE Introduction Video
MDE Composable BSS Video
Mavenir’s Charging Gateway Function Solution Brief
Mavenir’s Converged Charging Solution Brief
Mavenir’s Converge Charging System Video
Other MDE resources –
MDE Digital Marketplace Whitepaper
MDE solution For MVNOs & Digital Brands
MDE IoT Business Management Solution Brief
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
1 Analysys Mason/Mavenir White Paper “BSS digital overlay systems can help CSPs to maximize returns in the 5G era ” – June 2022
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005119/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom